

Special Issue

Liver Cancer: From Molecular Mechanism to Therapeutic Perspectives

Message from the Guest Editors

Modern cancer medicine is shifting its perspectives from a “one drug fits all” standpoint to an individualized approach, centered on the analysis of the cellular mechanisms involved in cancer development, such as evaluating the tumor microenvironment, investigating the immune cell composition, or finding new biomarkers. These studies established new molecular targets for different drug therapies which improved overall survival in hepatocellular carcinoma or cholangiocarcinoma; however, liver cancer still remains one of the leading causes of cancer-related deaths worldwide. Undoubtedly, there is a need for a thorough understanding of the mechanisms leading to disease progression and treatment resistance, in order to decrease its global burden. This Special Issues aims to cover both preclinical and clinical studies regarding cellular signaling pathways, experimental models for liver cancer, molecular targets, diagnostic or prognostic biomarkers, and novel therapies. We are confident that our research efforts will provide novel insights into the marked heterogeneity of this type of cancer, while concurrently offer new solutions for precision treatment.

Guest Editors

Dr. Tudor Mocan

Dr. Mirosław Kornek

Prof. Dr. Zeno Spârchez

Deadline for manuscript submissions

closed (31 January 2024)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/147013

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).